90 Miles From Tyranny

Friday, April 10, 2020

Video: Fake News Acosta Asks Trump If He Has ‘Investments in Hydroxychloroquine’

Dear Diary: Today I really zinged Drumpf good.

CNN’s fake news king Jim Acosta asked President Trump Wednesday if he had investments in the hydroxychloroquine drug, despite the fact that the claim has been proven completely false by several fact checkers.

‘No, I Don’t. Good Question’ the President deadpan replied as he walked out of the press briefing.

Trump on Obama: "He's know something [about Joe Biden] that you don't know. That I think I know. But you don't know." pic.twitter.com/gA30s1JnII
— Aaron Rupar (@atrupar) April 8, 2020

The story originated with leftists online, and graduated to the New York Times this week, which published a story Tuesday reporting that Trump has a small investment in Sanofi, which makes the brand-name Plaquenil.

The implication was that Trump is pushing hydroxychloroquine because he can make money from it.

However, the investment Trump has is so small that even the uber-liberal fact checker Snopes rated the Times story “Mostly False.”

The Daily Caller noted that “Trump’s personal stake in the company is estimated to be as small as $99.”

Trump stands to gain literally hundreds of cents from the investment!

Daily Caller

✔@DailyCaller

· Apr 8, 2020

Trump is asked by @Acosta if he has any investments in hydroxychloroquine.

"No I don't"

Snopes rated this claim "mostly false"https://dailycaller.com/2020/04/08/snopes-new-york-times-hydroxychloroquine-trump-finances-stake-investment/ …

*FiddleSticks*@NFrontone

He a small stake that comes out to 4 hundred dollars and some change...move on

2

9:05 PM - Apr 8, 2020

Twitter Ads info and privacy

See *FiddleSticks*'s other Tweets

Daily Caller

✔@DailyCaller

· Apr 8, 2020

Trump is asked by @Acosta if he has any investments in hydroxychloroquine.

"No I don't"

Snopes rated this claim "mostly false"https://dailycaller.com/2020/04/08/snopes-new-york-times-hydroxychloroquine-trump-finances-stake-investment/ …

Krista Hilton@KristaMHilton

If he has it bundled in a mutual fund... is that really an investment. He might not have even known it was there.... Snopes is a joke anyway.

66

7:27 PM - Apr 8, 2020

Twitter Ads info and privacy

See Krista Hilton's other Tweets

Daily Caller

✔@DailyCaller

· Apr 8, 2020

Trump is asked by @Acosta if he has any investments in hydroxychloroquine.

"No I don't"

Snopes rated this claim "mostly false"https://dailycaller.com/2020/04/08/snopes-new-york-times-hydroxychloroquine-trump-finances-stake-investment/ …

bobtripp@bobtripp10

If he owns it in a mutual then it’s splitting hairs! Stop the stupidity

2

7:17 PM - Apr 8, 2020

Twitter Ads info and privacy

See bobtripp's other Tweets

Daily Caller

✔@DailyCaller

· Apr 8, 2020

Trump is asked by @Acosta if he has any investments in hydroxychloroquine.

"No I don't"

Snopes rated this claim "mostly false"https://dailycaller.com/2020/04/08/snopes-new-york-times-hydroxychloroquine-trump-finances-stake-investment/ …

sdnerf@sdnerf

Trump has $500 (as a percentage) in a mutual fund in a blind trust. Agggggghhhhh

2

7:48 PM - Apr 8, 2020

Twitter Ads info and privacy

See sdnerf's other Tweets

Daily Caller

✔@DailyCaller

· Apr 8, 2020

Trump is asked by @Acosta if he has any investments in hydroxychloroquine.

"No I don't"

Snopes rated this claim "mostly false"https://dailycaller.com/2020/04/08/snopes-new-york-times-hydroxychloroquine-trump-finances-stake-investment/ …

M&M@realistxleft

Snopes is a divorced dude working out of his basement. Let’s get a fact check on that snopes.

5

8:55 PM - Apr 8, 2020

Twitter Ads info and privacy

See M&M's other Tweets

Of course, the media’s approach to anything now is ‘if orange man says it’s good, it must really be...

New Data Shows U.S. Companies Are Definitely Leaving China

U.S. companies are leaving China thanks to the trade war. They’ll leave even more thanks to the pandemic.

Sorry, Davos Man. Your China-led globalization is going out of style like bell bottoms.

Global manufacturing consulting firm Kearney released its seventh annual Reshoring Index on Tuesday, showing what it called a “dramatic reversal” of a five-year trend as domestic U.S. manufacturing in 2019 commanded a significantly greater share versus 14 Asian exporters tracked in the study. Manufacturing imports from China were the hardest hit.

Last year saw companies actively rethinking their supply chain, either convincing their Chinese partners to relocate to southeast Asia to avoid tariffs, or by opting out of sourcing from China altogether.

"Three decades ago, U.S. producers began manufacturing and sourcing in China for one reason: costs. The trade war brought a second dimension more fully into the equation―risk―as tariffs and the threat of disrupted China imports prompted companies to weigh surety of supply more fully alongside costs. COVID-19 brings a third dimension more fully into the mix, and arguably to the fore: resilience―the ability to foresee and adapt to unforeseen systemic shocks," says Patrick Van den Bossche, Kearney partner and co-author of the 19-page report.

The main beneficiaries of this are the smaller southeast Asian nations, led by Vietnam. And thanks to the passing of the U.S. Mexico Canada Agreement, Mexico, for all its problems with drug cartels, has become a favorite spot for sourcing.

In 2020, the trade war seemed to be on pause. Sadly, it gave way to a global pandemic that emanated from the Hubei province in China. The new SARS coronavirus has literally closed the economies of the Western world and created a public relations nightmare for China.

Not only that, companies were unable to get supply online in February and early March due to factory closures there, stalling business in the U.S.

Once China got up and running, the U.S. was hit between the eyes with the deadly COVID-19 disease caused by the rapidly spreading new SARS. Even if China was fully healed, the U.S was stuck in sick bay.

The full extent of the societal and economic trauma the coronavirus pandemic may cause is unknown still, the Kearney report’s authors wrote. But whatever the outcome, a return to status quo China trade pre-pandemic is unlikely.

Kearney predicts companies “will be compelled to go much further in rethinking their sourcing strategies, (and) their entire...